Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV-VLP) vaccine candidate across a series of dosing regimens. The interim analysis has shown that with a single dose administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) by Day 7. Further, the immune response was shown to be persistent through the six-month visit, including in the one-dose regimen.
{iframe}https://www.globenewswire.com/news-release/2019/04/16/1804556/0/en/Emergent-BioSolutions-Announces-Interim-Results-From-Phase-2-Study-Evaluating-CHIKV-VLP-Chikungunya-Virus-Vaccine-Candidate.html{/iframe}